Contrasting Echo Therapeutics (ECTE) and Tonix Pharmaceuticals Holding Corp. (TNXP)
Echo Therapeutics (OTCMKTS: ECTE) and Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.
This is a breakdown of recent ratings and price targets for Echo Therapeutics and Tonix Pharmaceuticals Holding Corp., as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Tonix Pharmaceuticals Holding Corp.||0||1||4||0||2.80|
Tonix Pharmaceuticals Holding Corp. has a consensus target price of $8.33, indicating a potential upside of 130.20%. Given Tonix Pharmaceuticals Holding Corp.’s higher possible upside, analysts plainly believe Tonix Pharmaceuticals Holding Corp. is more favorable than Echo Therapeutics.
This table compares Echo Therapeutics and Tonix Pharmaceuticals Holding Corp.’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Tonix Pharmaceuticals Holding Corp.||N/A||-78.25%||-73.14%|
Risk & Volatility
Echo Therapeutics has a beta of 1.68, indicating that its stock price is 68% more volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals Holding Corp. has a beta of 2.6, indicating that its stock price is 160% more volatile than the S&P 500.
Institutional & Insider Ownership
22.5% of Tonix Pharmaceuticals Holding Corp. shares are owned by institutional investors. 7.0% of Echo Therapeutics shares are owned by company insiders. Comparatively, 4.0% of Tonix Pharmaceuticals Holding Corp. shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Echo Therapeutics and Tonix Pharmaceuticals Holding Corp.’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Echo Therapeutics||$60,000.00||6.00||-$22.19 million||($1.28)||-0.02|
|Tonix Pharmaceuticals Holding Corp.||N/A||N/A||-$38.84 million||($3.38)||-1.07|
Echo Therapeutics has higher revenue and earnings than Tonix Pharmaceuticals Holding Corp.. Tonix Pharmaceuticals Holding Corp. is trading at a lower price-to-earnings ratio than Echo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Echo Therapeutics beats Tonix Pharmaceuticals Holding Corp. on 6 of the 10 factors compared between the two stocks.
Echo Therapeutics Company Profile
Echo Therapeutics, Inc. is a medical device company. The Company is engaged in developing a non-invasive, wireless continuous glucose monitoring (CGM) system with use in the wearable-health consumer market, diabetes outpatient market and in the hospital setting. The Company operates through the development of transdermal skin permeation and diagnostic medical devices segment. The Company has also developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, enhanced delivery of topical pharmaceuticals and other applications. The CGM System includes a skin preparation device, transdermal glucose sensor, battery and wireless transmitter. The Company has conducted several human feasibility clinical studies with its CGM System in healthy subjects, diabetics and critically ill patients, as well as a clinical study at several hospitals in the United States.
Tonix Pharmaceuticals Holding Corp. Company Profile
Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The companys lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden. Its lead product candidate includes TNX-102 SL, a cyclobenzaprine HCl sublingual tablet, which is in Phase III clinical stage for the treatment of PTSD; and Phase III clinical stage for the treatment of military-related PTSD. The companys product candidates also include TNX-601, an oral formulation of tianeptine oxalate for PTSD and cognitive dysfunction associated with steroid use; TNX-801, a smallpox-preventing vaccine based on a live synthetic version of horsepox virus; TNX-301, a fixed-dose combination drug product for alcohol use disorders; and TNX-701 for radiation injuries. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.
Receive News & Ratings for Echo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Echo Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.